Fig. 1

MET and HER2 expression levels in 033 T tumor sample. a Brain MRI showed a relatively well-demarcated enhancing mass in right frontal lobe. b Chest CT showed multiple masses, measuring up to 4 cm, in 033 T patient. c Genomic profiling of focal amplifications in 033 T patient derived tumor, PDXs, and PDX cells identified focal gains of MET and HER2. d Quantitative polymerase chain reaction gene copy number analysis was performed in order to detect MET and HER2 amplifications. NC; patient 694 T samples, used as negative controls, did not show MET and HER2 amplification. e MET, HER2, phosphorylated MET, phosphorylated HER2, and GAPDH as a loading control were analyzed using western blot. f Histologic comparison between the patient tumor sample and PDX tumor. The representative areas of each patient tumor sample and the corresponding PDXs were stained with H&E, MET, and HER2 antibodies. Fluorescence in situ hybridization of MET revealed amplification in many tumor cells (red dots). Silver in situ hybridization of HER2 showed amplification of HER2 in the patient tumor sample and PDX tumor (black dots). MET and HER2 immunohistochemical staining showed distinctive expression patterns in the patient-derived sample and PDX tumor sample (MET, HER2, ×200)